Literature DB >> 21120446

The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc.

Caihua Zhu1, Qin Chen, Zuoquan Xie, Jing Ai, Linjiang Tong, Jian Ding, Meiyu Geng.   

Abstract

Histone deacetylases (HDACs) play fundamental roles in the epigenetic regulation of gene expression and contribute to the growth, differentiation, and apoptosis of cancer cells. Although HDACs are recognized to be closely related to cancer development and altered expression of certain HDACs is observed in tumor samples, the arcane characters of HDACs in tumorigenesis have not been fully illustrated. Herein, we report that HDAC7 is a crucial player in cancer cell proliferation. Knockdown of HDAC7 resulted in significant G(1)/S arrest in different cancer cell lines. Subsequent investigations indicated that HDAC7 silencing blocked cell cycle progression through suppressing c-Myc expression and increasing p21 and p27 protein levels. The ectopic expression of c-Myc in turn antagonized the cell cycle arrest and repressed the elevation of p21 and p27 in HDAC7 silencing setting. Of note, HDAC7 deficiency was further identified to induce cellular senescence program, which was also reversed by c-Myc re-expression. Further chromatin immunoprecipitation assays indicated that HDAC7 directly binds with c-Myc gene and HDAC7 silencing decreased c-Myc mRNA level via reducing histone H3/H4 acetylation and repressing the association of RNA polymerase II (RNAP II) with c-Myc gene. Taken together, our findings highlight for the first time an unrecognized link between HDAC7 and c-Myc and offer a novel mechanistic insight into the contribution of HDAC7 to tumor progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120446     DOI: 10.1007/s00109-010-0701-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  34 in total

1.  Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression.

Authors:  H Y Kao; M Downes; P Ordentlich; R M Evans
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

Review 2.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 3.  Class II histone deacetylases: versatile regulators.

Authors:  Eric Verdin; Franck Dequiedt; Herbert G Kasler
Journal:  Trends Genet       Date:  2003-05       Impact factor: 11.639

4.  Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation.

Authors:  Amancio Carnero; David H Beach
Journal:  Oncogene       Date:  2004-08-05       Impact factor: 9.867

Review 5.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

6.  Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo.

Authors:  W Fischle; F Dequiedt; M Fillion; M J Hendzel; W Voelter; E Verdin
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

7.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

8.  Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis.

Authors:  Maud Martin; Michael Potente; Veerle Janssens; Didier Vertommen; Jean-Claude Twizere; Mark H Rider; Jozef Goris; Stefanie Dimmeler; Richard Kettmann; Franck Dequiedt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-13       Impact factor: 11.205

9.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.

Authors:  T D Littlewood; D C Hancock; P S Danielian; M G Parker; G I Evan
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

10.  Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis.

Authors:  Franck Dequiedt; Johan Van Lint; Emily Lecomte; Viktor Van Duppen; Thomas Seufferlein; Jackie R Vandenheede; Ruddy Wattiez; Richard Kettmann
Journal:  J Exp Med       Date:  2005-02-28       Impact factor: 14.307

View more
  26 in total

1.  HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.

Authors:  P Peixoto; V Castronovo; N Matheus; C Polese; O Peulen; A Gonzalez; M Boxus; E Verdin; M Thiry; F Dequiedt; D Mottet
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

2.  Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.

Authors:  Hideki Murata; Koji Yoshimoto; Ryusuke Hatae; Yojiro Akagi; Masahiro Mizoguchi; Nobuhiro Hata; Daisuke Kuga; Akira Nakamizo; Toshiyuki Amano; Tetsuro Sayama; Koji Iihara
Journal:  J Neurooncol       Date:  2015-08-14       Impact factor: 4.130

3.  HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance.

Authors:  Michaël Van Damme; Emerence Crompot; Nathalie Meuleman; Philippe Mineur; Dominique Bron; Laurence Lagneaux; Basile Stamatopoulos
Journal:  Epigenetics       Date:  2012-10-29       Impact factor: 4.528

4.  Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.

Authors:  Jian Fan; Bin Lou; Wei Chen; Jie Zhang; Sha Lin; Fei-fei Lv; Yu Chen
Journal:  Tumour Biol       Date:  2014-08-17

5.  Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling.

Authors:  Austin Hsu; Qiming Duan; Sarah McMahon; Yu Huang; Sarah Ab Wood; Nathanael S Gray; Biao Wang; Benoit G Bruneau; Saptarsi M Haldar
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 6.  Differential molecular mechanistic behavior of HDACs in cancer progression.

Authors:  Tashvinder Singh; Prabhsimran Kaur; Paramdeep Singh; Sandeep Singh; Anjana Munshi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

7.  HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.

Authors:  Corrado Caslini; Sunhwa Hong; Yuguang J Ban; Xi S Chen; Tan A Ince
Journal:  Oncogene       Date:  2019-08-02       Impact factor: 9.867

8.  The circRNA CNEACR regulates necroptosis of cardiomyocytes through Foxa2 suppression.

Authors:  Xiang-Qian Gao; Cui-Yun Liu; Yu-Hui Zhang; Yun-Hong Wang; Lu-Yu Zhou; Xin-Min Li; Kai Wang; Xin-Zhe Chen; Tao Wang; Jie Ju; Fei Wang; Shao-Cong Wang; Yin Wang; Zhao-Yang Chen; Kun Wang
Journal:  Cell Death Differ       Date:  2021-09-29       Impact factor: 12.067

9.  Targeting the acetylation signaling pathway in cancer therapy.

Authors:  Fabin Dang; Wenyi Wei
Journal:  Semin Cancer Biol       Date:  2021-03-08       Impact factor: 17.012

10.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.